Related Experiment Videos
[Midazolam administered orally as premedication in children in the ophthalmology department]
G Michalska-Krzanowska1, P Kowalczyk, K Dybkowska
1Zakładu Anestezjologii i Intensywnej Terapii Pomorskiej AM w Szczecinie.
Insights
Midazolam effectively provides deep sedation for pediatric ophthalmic procedures. Oral midazolam at 0.5 mg/kg ensures safe and optimal conditions for children undergoing diagnostics and minor surgeries.
Area of Science:
- Pediatric Anesthesiology
- Ophthalmic Surgery
- Pharmacology
Background:
- Preoperative sedation is crucial for pediatric patients undergoing ophthalmic procedures.
- Assessing the efficacy and safety of sedative agents is essential for optimizing patient care.
Purpose of the Study:
- To evaluate midazolam as a premedicant for children undergoing ophthalmic diagnostic and minor surgical procedures.
- To assess the deep sedation properties of midazolam in this pediatric population.
Main Methods:
- Oral midazolam administration at a dose of 0.5 mg/kg in children aged 2-10 years.
- Assessment of sedation using the Addenbrooke's Hospital Scale of Sedation.
- Monitoring of vital signs including systolic and diastolic arterial pressure (SAP, DAP), capillary blood oxygen saturation (SpO2), and heart rate (HR).
Main Results:
- Midazolam achieved good and optimal sedation levels for ophthalmic procedures in all pediatric patients.
- Sedation was deemed satisfactory and safe, with stable hemodynamic parameters (SAP, DAP, SpO2, HR) throughout the perioperative period.
- Midazolam demonstrated excellent sedative properties for children aged 2-10 years.
Conclusions:
- Oral midazolam is a safe and effective agent for preoperational medication in children undergoing ophthalmic procedures.
- Midazolam provides satisfactory deep sedation, facilitating diagnostic and minor surgical interventions in pediatric ophthalmology.
- The study supports the use of midazolam for optimizing sedation in pediatric ophthalmic surgery.
Abstract:
The aim of research was using midazolam for preoperational medication in children undergoing diagnostic and minor surgical procedures in ophthalmic surgery and estimation of its properties for deep sedation. We used midazolam in children of both sex, from 2 to 10 years of age. All the patients were considered as I or II grade of ASA scale of perioperational risk. Patients were given midazolam orally at dose 0.5 mg per kg of body weight. Sedation degree was assessed according to Addenbrooke's Hospital Scale of Sedation as well as to changes in systolic (SAP) and diastolic (DAP) arterial pressure, pulse oximetry of capillary blood (SpO2) and heart rate (HR). Sedation in all children subjected to the trial was good and optimal conditions to perform the procedures were achieved. We found the level of sedation satisfactory and safe. Measurement of SAP, DAP, SpO2 and HR revealed stability of circulation in the whole perioperative period. We found the sedative properties of midazolam as excellent in the described range of age and useful for the diagnostics and surgery respectively.